EUVIMEDEUVIMED entdecken
Open Access

Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems

Shaimaa Elshafie, Rou-Zhen Chen, Erfan Taherifard, Reshma Ramachandran, Joseph S Ross, Joshua D Wallach

JAMA Internal Medicine · 16.11.2026

DOI: 10.1001/jamainternmed.2026.5774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, online erschienen am 16.11.2026. Verfasst von Shaimaa Elshafie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.

Autor:innen und Institutionen

  • Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, Connecticut.
  • Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
  • Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.

Zitieren

APA

Elshafie, S., Chen, R. Z., Taherifard, E., Ramachandran, R., Ross, J. S., & Wallach, J. D. (2026). Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.5774

Vancouver

Elshafie S, Chen RZ, Taherifard E, Ramachandran R, Ross JS, Wallach JD. Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems. JAMA Internal Medicine. 2026. doi:10.1001/jamainternmed.2026.5774

BibTeX
@article{Elshafie2026,
  author = {Elshafie, Shaimaa and Chen, Rou-Zhen and Taherifard, Erfan and Ramachandran, Reshma and Ross, Joseph S and Wallach, Joshua D},
  title = {Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems},
  journal = {JAMA Internal Medicine},
  year = {2026},
  doi = {10.1001/jamainternmed.2026.5774}
}
Kostenlos starten →